Ellen N. Behrend, VMD, MS, PhD, DACVIM

Ellen Behrend, VMD, PhD, MS, DACVIM (SAIM), shares why she believes SGLT2 inhibitors could help more cats with diabetes receive treatment and discusses their potential role in managing complex cases, including cats with acromegaly.

Ellen Behrend, VMD, PhD, MS, DACVIM (SAIM), explains which feline patients may benefit from SGLT2 inhibitors, outlines key contraindications, and discusses the evolving conversation around cats with ketones.

Do feline diabetes diets need to change when a cat starts an SGLT2 inhibitor? Ellen Behrend, VMD, PhD, MS, DACVIM (SAIM), discusses what veterinarians should consider when balancing dietary recommendations, gastrointestinal adverse effects, and DKA concerns.

Concerns about diabetic ketoacidosis, ketone monitoring, and cost may prevent some veterinarians from considering SGLT2 for cats with diabetes. Ellen Behrend, VMD, PhD, MS, DACVIM (SAIM), discusses what monitoring is needed and how reduced monitoring requirements may help make these medications more affordable for owners.

Watch the short video to hear Ellen Behrend’s, VMD, PhD, MS, DACVIM (SAIM), answer.

A small animal internist answers the question in an interview with dvm360.

Ellen Behrend, VMD, PhD, MS, DACVIM (SAIM) discusses what is currently known about remission when on SGLT2 inhibitors.

An internal medicine specialist explains the answer to this question in an interview with dvm360.

Ellen Behrend, VMD, PhD, MS, DACVIM (SAIM), discusses several advantages to using an SGLT2 inhibitor in cats compared to insulin

Ellen Behrend, VMD, PhD, MS, DACVIM (SAIM), discusses what to monitor in cats on SGLT2 inhibitors, and how it differs from the monitoring required for patients on insulin

The most common adverse effects are gastrointestinal, says Ellen Behrend, VMD, PhD, MS, DACVIM (SAIM)

Ellen Behrend, VMD, PhD, MS, DACVIM (SAIM) explains the differences between bexagliflozin and velagliflozin, and how to determine if a patient is a good candidate

Ellen Behrend, VMD, PhD, MS, DACVIM (SAIM), describes a sodium-glucose cotransporter-2 inhibitor in a dvm360 interview.

Owning a diabetic cat gave this internist additional insights into how best to manage diabetic cats at home.